Camurus: Advancing Patient Care Through Innovation with FluidCrystal®
Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are formulated and administered to achieve optimal therapeutic effect. These drugs are primarily used in type 2 diabetes and obesity treatment. 🧬 What Are Incretins?Incretins are hormones released by the gut […]
The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan Paperback – June 3, 2025
by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds uncovers the cellular mechanisms behind GLP-1s and other peptides that can help people lose significant weight and treat type-2 diabetes. Importantly, Dr. Seeds has also gathered peer-reviewed research that shows […]
Nourishing GLP-1 Therapy for Obesity
This academic article, “Nutritional priorities to support GLP‐1 therapy for obesity,” is a joint advisory from several prominent American health organizations. It examines the use of GLP-1 receptor agonists (GLP-1s) for obesity treatment, highlighting their efficacy in weight reduction and other clinical benefits while also addressing significant challenges like gastrointestinal side effects, potential nutrient deficiencies, and loss of muscle and bone mass. The authors […]
MAHA Agenda Excludes GLP-1 Coverage Expansion
PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo Nordisk. Although a Biden-era proposal to expand coverage was rejected due to concerns about the high cost to the federal government, […]
The Ozempic Era and Shifting Obesity Blame
Schmidt, Laura A., and Luc L. Hagenaars. “The Ozempic Era Could Shift Blame for Obesity From Individuals to Commercial Food Systems.” Issues in Science and Technology 41, no. 3 (Spring 2025): 24–26. https://doi.org/10.58875/TEQC7966 Laura A. Schmidt is a professor of health policy in the School of Medicine at the University of California, San Francisco. Luc L. Hagenaars is assistant professor […]
Is Obesity Genetic or Environmental? YES!
Vocabulary-GWAS – A Genome-Wide Association Study – a research method used to identify genetic variations (like single nucleotide polymorphisms or SNPs) associated with a specific disease or trait. It involves comparing the genomes of individuals with the disease or trait to those without it to find variations that occur more frequently in the affected group. SNP […]
GLP-1 RAs: Psychiatric, Cognitive, and Quality of Life Effects
This meta-analysis examines the impact of Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RAs), medications used for obesity and diabetes, on the mental health and quality of life of patients. The study analyzed data from 80 randomized clinical trials involving over 107,000 participants with overweight, obesity, or diabetes. Crucially, it found no significant increase in the risk of serious or […]
Novo Nordisk Partners with Telehealth for Wegovy Promotion
May 23, 2025Stat + by Katie Palmer https://ro.co/ https://lifemd.com/ Stat + reports on the evolving landscape of GLP-1 drug marketing, noting a shift in the relationship between major pharmaceutical companies like Novo Nordisk and telehealth providers. After previously battling telehealth companies offering compounded versions of their drugs, Novo Nordisk is now collaborating with specific telehealth platforms, including Ro and LifeMD. This partnership […]
Cysteine Deficiency Drives Weight Loss by Depleting CoA
This research paper explores the impact of amino acid restriction on weight loss, focusing on the unique effects of cysteine deficiency. The study demonstrates that cysteine restriction in mice, particularly those with compromised cysteine synthesis, leads to rapid and significant weight loss, primarily through fat reduction. This weight loss is linked to the activation of stress responses, reduced levels of key metabolites like CoA, and resulting metabolic inefficiency, […]
MCED Test Performance in Obese Individuals
This abstract evaluates a multi-cancer early detection (MCED) blood test specifically designed for individuals with obesity, a group at higher risk for several cancers often without standard screening. The study investigated the test’s ability to accurately detect cancer and identify the tissue of origin using a two-step methylation profiling method. Results showed the test had a high positive predictive value (PPV) and reasonable sensitivity, […]